Avidity NanoMedicines closes $6M convertible note financing, expands investor syndicate

NewsGuard 100/100 Score

Avidity NanoMedicines today announced that it has expanded its investor syndicate through the closing of a $6 million convertible note financing co-led by Fidelity Biosciences and TPG Biotech. Other investors in the financing include Brace Pharmaceuticals, Partner Fund Management, L.P. and existing investor Alethea Capital Management. Ben Auspitz from Fidelity Biosciences and Eran Nadav, Ph.D. from TPG Biotech will join Avidity's board as observers. Proceeds from the financing will be used to advance new cancer therapies that utilize the company's proprietary antibody-siRNA complex (ARC™) platform.

Avidity is based on pioneering nanoparticle technology developed by Mark Davis, Schlinger Professor of Chemical Engineering at Caltech. Avidity NanoMedicines was founded to advance a new class of therapeutics, antibody-siRNA complexes (ARCsTM), which employ antibody-targeted nanoparticles containing siRNA payloads. The technology draws on the precise targeting associated with antibody-drug conjugates and the exquisite selectivity of nucleic acid-based medicines.

"Avidity NanoMedicines has recruited an exceptional team and is working on a fundamentally important problem – namely, the targeted delivery of nucleic acids to tumor cells and tissues outside the liver," said Ben Auspitz, Partner at Fidelity Biosciences. "We have been impressed with the strategy and the science, and we are enthusiastic supporters of the continued evolution of Avidity."

"Over the past several years, we have witnessed a resurgence in RNA interference and other nucleic acid-based therapeutic approaches," added Eran Nadav, Ph.D., Partner and Managing Director at TPG Biotech. "We are now at an inflection point where advances in material and polymer science could enable a transformative shift in cancer treatment."

"The promise and potential of targeted delivery has been a long-standing goal in the field of nucleic acid-based medicines," said Troy Wilson, Ph.D., J.D., President, Chief Executive Officer and co-founder of Avidity NanoMedicines. "We are taking Mark Davis' pioneering efforts in nanoparticle-based therapeutics, and building on them to advance breakthrough therapies in oncology. We are delighted to welcome these new investors to Avidity as our partners to realize this vision."



The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New cancer projections show increased prostate cases by 25% in 2050, despite prevention efforts